The Dark Side of Sphingolipids: Searching for Potential Cardiovascular Biomarkers
Biomolecules · 2023
DOI: 10.3390/biom13010168 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, 2023. Verfasst von Paola Di Pietro und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, 84081 Baronissi, Italy. Hauptthemen laut MEDLINE: Sphingolipids, Ceramides. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 160 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health—Young Researcher project.
Abstract (Originalsprache)
Cardiovascular diseases (CVDs) are the leading cause of death and illness in Europe and worldwide, responsible for a staggering 47% of deaths in Europe. Over the past few years, there has been increasing evidence pointing to bioactive sphingolipids as drivers of CVDs. Among them, most studies place emphasis on the cardiovascular effect of ceramides and sphingosine-1-phosphate (S1P), reporting correlation between their aberrant expression and CVD risk factors. In experimental in vivo models, pharmacological inhibition of de novo ceramide synthesis averts the development of diabetes, atherosclerosis, hypertension and heart failure. In humans, levels of circulating sphingolipids have been suggested as prognostic indicators for a broad spectrum of diseases. This article provides a comprehensive review of sphingolipids’ contribution to cardiovascular, cerebrovascular and metabolic diseases, focusing on the latest experimental and clinical findings. Cumulatively, these studies indicate that monitoring sphingolipid level alterations could allow for better assessment of cardiovascular disease progression and/or severity, and also suggest them as a potential target for future therapeutic intervention. Some approaches may include the down-regulation of specific sphingolipid species levels in the circulation, by inhibiting critical enzymes that catalyze ceramide metabolism, such as ceramidases, sphingomyelinases and sphingosine kinases. Therefore, manipulation of the sphingolipid pathway may be a promising strategy for the treatment of cardio- and cerebrovascular diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, 84081 Baronissi, Italy.
- Vascular Physiopathology Unit, IRCCS Neuromed, 86077 Pozzilli, Italy.
- Department of Pharmacy, University of Salerno, 84084 Fisciano, Italy.
ORCID-Profile: Paola Di Pietro, Carmine Izzo, Maria Rosaria Rusciano, Valeria Visco, Michele Ciccarelli, Albino Carrizzo
Förderung
- Italian Ministry of Health—Young Researcher project
Zitieren
APA
Di Pietro, P., Izzo, C., Abate, A. C., Iesu, P., Rusciano, M. R., Venturini, E., Visco, V., Sommella, E., Ciccarelli, M., Carrizzo, A., & Vecchione, C. (2023). The Dark Side of Sphingolipids: Searching for Potential Cardiovascular Biomarkers. Biomolecules. https://doi.org/10.3390/biom13010168
Vancouver
Di Pietro P, Izzo C, Abate AC, Iesu P, Rusciano MR, Venturini E, et al. The Dark Side of Sphingolipids: Searching for Potential Cardiovascular Biomarkers. Biomolecules. 2023. doi:10.3390/biom13010168
BibTeX
@article{DiPietro2023,
author = {Di Pietro, Paola and Izzo, Carmine and Abate, Angela Carmelita and Iesu, Paola and Rusciano, Maria Rosaria and Venturini, Eleonora and Visco, Valeria and Sommella, Eduardo and Ciccarelli, Michele and Carrizzo, Albino and Vecchione, Carmine},
title = {The Dark Side of Sphingolipids: Searching for Potential Cardiovascular Biomarkers},
journal = {Biomolecules},
year = {2023},
doi = {10.3390/biom13010168}
}
EUVIMED